AUSTIN, Texas, March 29, 2018 /PRNewswire/ — Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price of $5.00 per share, before underwriting discounts.
AUSTIN, Texas, Oct. 13, 2017 /PRNewswire/ — Genprex, Inc., (“Genprex”) a clinical stage gene therapy company, today announced that its initial public offering of a minimum of 2.5 million shares and a maximum of 4.5 million shares of its common stock has priced at $5.00 per share.
Genprex expects the offering to close on or about November 6, 2017, subject to completion of the minimum offering and other customary closing conditions, and that its shares will begin trading on the NASDAQ Capital Market under the symbol “GNPX” shortly after closing….
AUSTIN, TX, July 21, 2017 – Genprex, Inc. a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined….
AUSTIN, TX, April 2, 2017 – Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice….
AUSTIN, Texas, March 27, 2017 — Genprex, Inc., a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, today announced that Julien Pham, MD, the Company’s Chief Operating Officer, is scheduled to present a corporate overview at two upcoming healthcare investor conferences.
Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 PM EDT in New York, NY
BioCentury 24th Annual Future Leaders in Biotech Industry – Friday, April 7, 2017 at 11:20 AM EDT in New York, NY
Genprex is a privately held, clinical-stage biopharmaceutical company developing immunogene therapy treatments to increase the treatment options for various cancers….
AUSTIN, TX, January 6, 2017 – Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients.
The clinical trial, which is ongoing at The University of Texas MD Anderson Cancer Center, is designed to evaluate the Oncoprex/erlotinib treatment combination in up to 57 patients with late stage NSCLC, with and without EGFR mutations, who have failed at least two drug regimens….
AUSTIN, TX, December 19, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference, one of largest healthcare focused investor conferences in the U.S….
AUSTIN, TX, December 7, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that it has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program. The program will combine investor relations, public relations and digital communications to advance the objective of raising the profile of Genprex and its lead candidate Oncoprex, which is currently in a Phase II trial for the treatment of non-small cell lung cancer (NSCLC)….
AUSTIN, TX, November 4, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer. Dr. Pham joins Genprex after previously serving as Founder and Chief Medical Officer at RubiconMD and as a clinical faculty member at Harvard Medical School….
AUSTIN, TX, August 24, 2016 – Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate. Upon completion of the initial phase of this agreement, which is expected to occur well before the end of this year, the Company intends to put in place an overall plan with Network 1 Financial to provide for its immediate and long term capital needs and for the ultimate goal of being a public company….